Want to see ABSI full AI Analyst Report?
ABSI Stock Chart & Stats
$3.58
$0.12(3.91%)
At close: 4:00 PM EST
$3.58
$0.12(3.91%)
Day’s Range― - ―
52-Week Range$2.24 - $12.06
Previous CloseN/A
Volume51.94M
Average Volume (3M)7.22M
Market Cap
$1.94B
Enterprise Value$1.12B
Total Cash (Recent Filing)$125.70M
Total Debt (Recent Filing)$4.42M
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Aug 18, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding169,400,330
10 Day Avg. Volume5,894,879
30 Day Avg. Volume7,220,871
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.52
Price to Sales (P/S)170.48
P/FCF Ratio-5.08
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue607.40
Enterprise Value/Gross Profit-46.12
Enterprise Value/Ebitda-10.44
Forecast
1Y Price Target
$13.38Price Target Upside273.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$5.76M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetAbSci's extremely low leverage and relatively large equity base reduce near‑term refinancing and solvency risk, giving management durable financial optionality to fund clinical programs, pursue partnerships or weather trial timing variability without immediate forced restructuring over the next 2–6 months.
AI-driven Platform And Efficiency GainsThe company's agentic AI and high-throughput experimental stack represents a structural competitive advantage: it can shorten design cycles, scale discovery, and lower per‑candidate costs. Platform leverage also supports pipeline expansion and makes Absci a more attractive partner for biopharma collaborations over the medium term.
Lead Program Clinical Progress And Favorable PKABS‑201's favorable Phase I safety and long half‑life support an infrequent dosing profile that can materially enhance patient adoption and commercial differentiation. The defined interim and full POC timelines provide clear upcoming de‑risking catalysts and support realistic program advancement planning.
Bears Say
High Cash BurnSustained, large negative operating and free cash flow indicate the business is capital intensive and reliant on external funding. Even with existing cash, continued high burn creates financing sensitivity if timelines slip or costs rise, increasing dilution or partnership dependence risk over the medium term.
Minimal And Declining RevenueRevenue is negligible and falling, highlighting Absci's dependence on milestone/partner payments and capital markets. Lack of recurring commercial revenue weakens resilience to execution delays and limits internal funding capacity for R&D growth without dilutive financings or new partner deals.
Clinical And Regulatory Uncertainty / Placebo RiskThe business outcome hinges on upcoming trial readouts that are binary in nature; directional interim signals and significant endometriosis placebo risk mean trial outcomes could delay approvals, increase capital needs, or force strategy shifts, materially affecting long‑term prospects if results disappoint.
AbSci News
ABSI FAQ
What was Absci Corp.’s price range in the past 12 months?
Absci Corp. lowest stock price was $2.24 and its highest was $12.05 in the past 12 months.
What is Absci Corp.’s market cap?
Absci Corp.’s market cap is $1.94B.
When is Absci Corp.’s upcoming earnings report date?
Absci Corp.’s upcoming earnings report date is Aug 18, 2026 which is in 38 days.
How were Absci Corp.’s earnings last quarter?
Absci Corp. released its earnings results on May 07, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.199 by $0.009.
Is Absci Corp. overvalued?
According to Wall Street analysts Absci Corp.’s price is currently Undervalued.
Does Absci Corp. pay dividends?
Absci Corp. does not currently pay dividends.
What is Absci Corp.’s EPS estimate?
Absci Corp.’s EPS estimate is -0.19.
How many shares outstanding does Absci Corp. have?
Absci Corp. has 169,400,330 shares outstanding.
What happened to Absci Corp.’s price movement after its last earnings report?
Absci Corp. reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.199. Following the earnings report the stock price went up 2.609%.
Which hedge fund is a major shareholder of Absci Corp.?
Currently, no hedge funds are holding shares in ABSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbSci Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.38 (273.60% Upside)
$13.38 (273.60% Upside)
Blogger Sentiment
Bullish
ABSI Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $349.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 8.5%
Last 30 Days ▲ 8.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
288.27%
12-Months-Change
Fundamentals
Return on Equity
-63.58%
Trailing 12-Months
Asset Growth
-15.85%
Trailing 12-Months
Company Description
Absci Corp.
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
ABSI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear progress on the lead program (ABS-201) with favorable early safety/PK signals, supportive PK modeling for an infrequent dosing profile, a defined clinical timeline (interim 13-week readout in H2 2026 and full 26-week POC in early 2027), and a substantial addressable market supported by consumer and KOL research. The company expanded its prolactin-focused pipeline (ABS-202), sharpened strategic focus by de‑emphasizing oncology, and reported a cash runway into H1 2028. Offsetting these positives are a very small quarter revenue base ($200k), a cash decline of ~12.9% QoQ to $125.7M, increased R&D spend (+17.7% YoY), and remaining clinical and regulatory risks (directional 13-week readout, placebo risk in endometriosis). Overall, the call emphasized promising clinical and commercial potential but also highlighted near-term execution and financing sensitivities.View all ABSI earnings summariesABSI Stock 12 Month Forecast
Average Price Target
$13.38
▲(273.60% Upside)
Technical Analysis
Autolus Therapeutics
―
―
ADC Therapeutics
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
6.13% Insiders
17.83% Mutual Funds
0.05% Other Institutional Investors
56.96% Public Companies and
Individual Investors